Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CONCERT PHARMACEUTICALS, INC.CNCE · Entity 115906 | Director | June 14, 2018 | June 18, 2018 |
| CYTOKINETICS INCCYTK · Entity 3528 | Director | July 15, 2025 | July 16, 2025 |
| Crinetics Pharmaceuticals, Inc.CRNX · Entity 3579 | Director | June 11, 2025 | June 13, 2025 |
| Ocera Therapeutics, Inc.OCRX · Entity 171193 | Director | December 11, 2017 | December 11, 2017 |
| SEELOS THERAPEUTICS, INC.APRI · Entity 93662 | Director | January 04, 2018 | January 08, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CONCERT PHARMACEUTICALS, INC.
Report date June 14, 2018 · Filed June 18, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Nonstatutory Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.59 · Expires 2028-06-13 | Direct | 10,000 |
Reported balance
After 2018-06-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-14 · Grant · Acquired 10,000 · Balance 10,000 F1: The shares underlying this option vest in equal quarterly installments over a one-year period, through and including June 14, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest in equal quarterly installments over a one-year period, through and including June 14, 2019.
CYTOKINETICS INC
Report date July 15, 2025 · Filed July 16, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 32,345 |
Reported balance
After 2025-07-15 transaction · row 1
1 source rowRow 1 · 2025-07-15 · Grant · Acquired 164 · Balance 32,345 F1: Director equity in lieu of cash retainer program. |
Filing footnotes · ownership attribution and instrument terms
F1: Director equity in lieu of cash retainer program.
Crinetics Pharmaceuticals, Inc.
Report date June 11, 2025 · Filed June 13, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 116,146 |
Reported balance
After 2025-06-11 transaction · row 1
1 source rowRow 1 · 2025-06-11 · Grant · Acquired 6,900 · Balance 116,146 F1: The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 100% vesting on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.33 · Expires 2035-06-11 | Direct | 10,350 |
Reported balance
After 2025-06-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-06-11 · Grant · Acquired 10,350 · Balance 10,350 F2: The stock option shall vest and become exercisable on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 100% vesting on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.
F2: The stock option shall vest and become exercisable on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.
Ocera Therapeutics, Inc.
Report date December 11, 2017 · Filed December 11, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-12-11 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2017-12-11 · Disposition to issuer · Disposed 5,000 · Balance 0 F1: Pursuant to an Agreement and Plan of Merger, dated November 1, 2017 (the "Merger Agreement"), by and between Ocera Therapeutics, Inc., a Delaware corporation (the "Issuer"), MAK LLC, a Delaware limited liability company ("Parent"), MEH Acquisition Co., a Delaware corporation and a direct wholly-owned subsidiary of Parent ("Purchaser"), and for limited purposes, Mallinckrodt plc, an Irish public limited company and the ultimate parent entity of Parent and Purchaser ("Mallinckrodt"), Purchaser was merged with and into Issuer on December 11, 2017, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). F2: (Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, all shares of common stock, $0.00001 par value per share (the "Shares"), of the Issuer outstanding immediately prior to the effective time of the Merger (the "Effective Time") , were canceled and converted automatically and without any required action on the part of the Reporting Person into the right to receive (i) $1.52 per Share in cash, without interest, plus (ii) one non-transferable contingent value right per Share (each, a "CVR"), which represents the contractual right under a contingent value rights agreement, by and among Parent, Continental Stock Transfer & Trust Company, and for limited purposes, Mallinckrodt (the "CVR Agreement"), entered into on December 7, 2017 to receive one or more payments in cash currently estimated to be up to $2.58 per Share, contingent upon the achievement of certain milestones, in each case, less any required withholding taxes. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-12-11 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2017-12-11 · Disposition to issuer · Disposed 12,500 · Balance 0 F1: Pursuant to an Agreement and Plan of Merger, dated November 1, 2017 (the "Merger Agreement"), by and between Ocera Therapeutics, Inc., a Delaware corporation (the "Issuer"), MAK LLC, a Delaware limited liability company ("Parent"), MEH Acquisition Co., a Delaware corporation and a direct wholly-owned subsidiary of Parent ("Purchaser"), and for limited purposes, Mallinckrodt plc, an Irish public limited company and the ultimate parent entity of Parent and Purchaser ("Mallinckrodt"), Purchaser was merged with and into Issuer on December 11, 2017, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). F2: (Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, all shares of common stock, $0.00001 par value per share (the "Shares"), of the Issuer outstanding immediately prior to the effective time of the Merger (the "Effective Time") , were canceled and converted automatically and without any required action on the part of the Reporting Person into the right to receive (i) $1.52 per Share in cash, without interest, plus (ii) one non-transferable contingent value right per Share (each, a "CVR"), which represents the contractual right under a contingent value rights agreement, by and among Parent, Continental Stock Transfer & Trust Company, and for limited purposes, Mallinckrodt (the "CVR Agreement"), entered into on December 7, 2017 to receive one or more payments in cash currently estimated to be up to $2.58 per Share, contingent upon the achievement of certain milestones, in each case, less any required withholding taxes. F3: At the Effective Time of the Merger, each restricted stock unit outstanding, automatically and without any required action on the part of the Reporting Person, became fully vested and canceled in exchange for a right to receive, for each share of common stock underlying the restricted stock unit, (i) an amount in cash, equal to $1.52, without interest plus (ii) one CVR, less any required withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.25 · Expires 2023-12-19 | Direct | 0 |
Reported balance
After 2017-12-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-12-11 · Disposition to issuer · Disposed 20,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an "In the Money Option") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR. F5: (Continued from Footnote 4) All other options (each, an "Out of the Money Option") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option. Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore. F6: This Out of the Money Option, which provided for vesting with respect to 25% of such options on December 19, 2014, with the remaining 75% of such options vesting in equal monthly installments over the next succeeding three year period, was cancelled in connection with the Merger for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.84 · Expires 2024-06-11 | Direct | 0 |
Reported balance
After 2017-12-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-12-11 · Disposition to issuer · Disposed 10,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an "In the Money Option") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR. F5: (Continued from Footnote 4) All other options (each, an "Out of the Money Option") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option. Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore. F7: This Out of the Money Option, which became fully vested on July 11, 2015, was cancelled in connection with the Merge for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.76 · Expires 2025-06-17 | Direct | 0 |
Reported balance
After 2017-12-11 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2017-12-11 · Disposition to issuer · Disposed 10,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an "In the Money Option") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR. F5: (Continued from Footnote 4) All other options (each, an "Out of the Money Option") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option. Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore. F8: This Out of the Money Option, which became fully vested on June 18, 2016, was cancelled in connection with the Merger in exchange for the right to receive one or more cash payments, without interest and subject to deduction for any required withholding taxes, equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds $3.76, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.26 · Expires 2026-06-13 | Direct | 0 |
Reported balance
After 2017-12-11 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2017-12-11 · Disposition to issuer · Disposed 12,500 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an "In the Money Option") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR. F5: (Continued from Footnote 4) All other options (each, an "Out of the Money Option") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option. Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore. F9: This Out of the Money Option, which became fully vested on June 14, 2017, was cancelled in connection with the Merger in exchange for the right to receive one or more cash payments, without interest and subject to deduction for any required withholding taxes, equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds $2.26, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to an Agreement and Plan of Merger, dated November 1, 2017 (the "Merger Agreement"), by and between Ocera Therapeutics, Inc., a Delaware corporation (the "Issuer"), MAK LLC, a Delaware limited liability company ("Parent"), MEH Acquisition Co., a Delaware corporation and a direct wholly-owned subsidiary of Parent ("Purchaser"), and for limited purposes, Mallinckrodt plc, an Irish public limited company and the ultimate parent entity of Parent and Purchaser ("Mallinckrodt"), Purchaser was merged with and into Issuer on December 11, 2017, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger").
F2: (Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, all shares of common stock, $0.00001 par value per share (the "Shares"), of the Issuer outstanding immediately prior to the effective time of the Merger (the "Effective Time") , were canceled and converted automatically and without any required action on the part of the Reporting Person into the right to receive (i) $1.52 per Share in cash, without interest, plus (ii) one non-transferable contingent value right per Share (each, a "CVR"), which represents the contractual right under a contingent value rights agreement, by and among Parent, Continental Stock Transfer & Trust Company, and for limited purposes, Mallinckrodt (the "CVR Agreement"), entered into on December 7, 2017 to receive one or more payments in cash currently estimated to be up to $2.58 per Share, contingent upon the achievement of certain milestones, in each case, less any required withholding taxes.
F3: At the Effective Time of the Merger, each restricted stock unit outstanding, automatically and without any required action on the part of the Reporting Person, became fully vested and canceled in exchange for a right to receive, for each share of common stock underlying the restricted stock unit, (i) an amount in cash, equal to $1.52, without interest plus (ii) one CVR, less any required withholding taxes.
F4: Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an "In the Money Option") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR.
F5: (Continued from Footnote 4) All other options (each, an "Out of the Money Option") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option. Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore.
F6: This Out of the Money Option, which provided for vesting with respect to 25% of such options on December 19, 2014, with the remaining 75% of such options vesting in equal monthly installments over the next succeeding three year period, was cancelled in connection with the Merger for no consideration.
F7: This Out of the Money Option, which became fully vested on July 11, 2015, was cancelled in connection with the Merge for no consideration.
F8: This Out of the Money Option, which became fully vested on June 18, 2016, was cancelled in connection with the Merger in exchange for the right to receive one or more cash payments, without interest and subject to deduction for any required withholding taxes, equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds $3.76, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option.
F9: This Out of the Money Option, which became fully vested on June 14, 2017, was cancelled in connection with the Merger in exchange for the right to receive one or more cash payments, without interest and subject to deduction for any required withholding taxes, equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds $2.26, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option.
SEELOS THERAPEUTICS, INC.
Report date January 04, 2018 · Filed January 08, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.11 · Expires 2028-01-04 | Direct | 35,000 |
Reported balance
After 2018-01-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-01-04 · Grant · Acquired 35,000 · Balance 35,000 F1: The options to purchase shares of common stock were issued to the Reporting Person, a non-employee director of Issuer, as an annual stock option grant for his service as a director of the Issuer. F2: The options shall vest with respect to 1/12th of the underlying shares monthly, commencing with the first monthly vesting date of February 4, 2018, so that such options are fully vested on January 4, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: The options to purchase shares of common stock were issued to the Reporting Person, a non-employee director of Issuer, as an annual stock option grant for his service as a director of the Issuer.
F2: The options shall vest with respect to 1/12th of the underlying shares monthly, commencing with the first monthly vesting date of February 4, 2018, so that such options are fully vested on January 4, 2019.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2022 Filed Jul 12, 2022 20:37 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 137 | $41.00 | $5,617.00 |
DisclosureSEC source: 0001127602-22-019241 · form4.xml · nonDerivative · entry 1 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,170 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are fully vested from the moment of grant. Shares are issued at per share price of $41.00, representing the closing stock price of the Issuer's common stock on July 1, 2022. Read SEC document |
| June 17, 2022 Filed Jun 21, 2022 20:48 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantStock Option (right to buy) · Derivative | 17,500 | $0.00 Strike: $18.29 | $0.00 |
DisclosureSEC source: 0001209191-22-038442 · doc4.xml · derivative · entry 1 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2032-06-16 F1 · derivative.exercise_date: The entire number of shares subject to this option become fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| May 10, 2022 Filed May 11, 2022 22:07 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $37.89 | $0.00 |
DisclosureSEC source: 0001061983-22-000122 · edgardoc.xml · derivative · entry 2 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2032-05-10 F2 · derivative.exercise_date: Options shall vest and become exercisable in 12 equal monthly installments, the first such installment vesting on 06/10/2022 and the last such installment vesting on 05/10/2023. Read SEC document |
| May 10, 2022 Filed May 11, 2022 22:07 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001061983-22-000122 · edgardoc.xml · nonDerivative · entry 1 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,033 F1 · kind: Comprised of restricted stock units that will vest in full and in one installment on 05/10/2023. Read SEC document |
| April 01, 2022 Filed Apr 1, 2022 23:17 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 146 | $38.38 | $5,603.48 |
DisclosureSEC source: 0001061983-22-000090 · edgardoc.xml · nonDerivative · entry 1 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,033 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are fully vested from the moment of grant. Shares issued at per share price of $38.38, representing the Issuer's closing stock price on April 1, 2022. Read SEC document |
| January 03, 2022 Filed Jan 4, 2022 21:48 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 122 | $46.00 | $5,612.00 |
DisclosureSEC source: 0001061983-22-000013 · edgardoc.xml · nonDerivative · entry 1 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,887 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are full vested from the moment of grant. Shares issued at per share price of $46.00, representing the Issuer's closing stock price on January 3, 2022. F2 · balance_after: Amount includes 1,887 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document |
| December 27, 2021 Filed Dec 28, 2021 22:16 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 4,166 | $0.00 Strike: $5.46 | $0.00 |
DisclosureSEC source: 0001061983-21-000269 · edgardoc.xml · derivative · entry 3 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,166 shares Expires 2022-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 27, 2021 Filed Dec 28, 2021 22:16 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 4,166 | $44.37 | $184,854.17 |
DisclosureSEC source: 0001061983-21-000269 · edgardoc.xml · nonDerivative · entry 2 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,765 F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on November 24, 2021. F2 · balance_after: Amount includes 1,765 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document |
| December 27, 2021 Filed Dec 28, 2021 22:16 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 4,166 | $5.46 | $22,746.36 |
DisclosureSEC source: 0001061983-21-000269 · edgardoc.xml · nonDerivative · entry 1 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,931 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on November 24, 2021. F2 · balance_after: Amount includes 1,765 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document |
| October 01, 2021 Filed Oct 4, 2021 23:03 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 306 | $36.74 | $11,242.44 |
DisclosureSEC source: 0001061983-21-000232 · edgardoc.xml · nonDerivative · entry 1 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,765 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are full vested from the moment of grant. Shares issued at per share price of $36.74, representing the Issuer's closing stock price on October 1, 2021. F2 · balance_after: Amount includes 1,765 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document |
| July 07, 2021 Filed Jul 8, 2021 21:32 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 63 | $19.77 | $1,245.51 |
DisclosureSEC source: 0001061983-21-000194 · edgardoc.xml · nonDerivative · entry 1 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,459 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are full vested from the moment of grant. Shares issued at per share price of $19.77, representing the Issuer's closing stock price on July 7, 2021. F2 · balance_after: Amount includes 1,459 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 20:44 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 476 | $20.98 | $9,986.48 |
DisclosureSEC source: 0001061983-21-000170 · edgardoc.xml · nonDerivative · entry 1 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,396 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are full vested from the moment of grant. Shares issued at per share price of $20.98, representing the Issuer's closing stock price on July 1, 2021. F2 · balance_after: Amount includes 1,396 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document |
| June 22, 2021 Filed Jun 23, 2021 21:00 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantStock Option (right to buy) · Derivative | 17,500 | $0.00 Strike: $20.23 | $0.00 |
DisclosureSEC source: 0001209191-21-042769 · doc4.xml · derivative · entry 1 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2031-06-21 F1 · derivative.exercise_date: The entire number of shares subject to this option become fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| May 12, 2021 Filed May 14, 2021 00:04 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $24.32 | $0.00 |
DisclosureSEC source: 0001061983-21-000145 · edgardoc.xml · derivative · entry 2 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-05-12 F3 · derivative.exercise_date: Options shall vest and become exercisable in 12 equal monthly installments, the first such installment vesting on 06/12/2021 and the last such installment vesting on 05/12/2022. Read SEC document |
| May 12, 2021 Filed May 14, 2021 00:04 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001061983-21-000145 · edgardoc.xml · nonDerivative · entry 1 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,920 F1 · kind: Comprised of restricted stock units that will vest in full and in one installment on 05/12/2022. F2 · balance_after: Amount includes 920 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 21:48 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 409 | $24.44 | $9,995.96 |
DisclosureSEC source: 0001061983-21-000100 · edgardoc.xml · nonDerivative · entry 1 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 920 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are full vested from the moment of grant. Shares issued at per share price of $24.44, representing the Issuer's closing stock price on April 1, 2021. F2 · balance_after: Amount includes 920 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 23:19 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 511 | $19.56 | $9,995.16 |
DisclosureSEC source: 0001061983-21-000017 · edgardoc.xml · nonDerivative · entry 1 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 511 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are full vested from the moment of grant. Shares issued at per share price of $19.56, representing the Issuer's closing stock price on January 4, 2021. F2 · balance_after: Amount includes 511 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document |
| June 19, 2020 Filed Jun 22, 2020 20:17 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $23.23 | $0.00 |
DisclosureSEC source: 0001209191-20-038153 · doc4.xml · derivative · entry 1 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2030-06-18 F1 · derivative.exercise_date: The entire number of shares subject to this option become fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| May 13, 2020 Filed May 14, 2020 20:46 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $21.61 Strike: $21.61 | $432,200.00 |
DisclosureSEC source: 0001061983-20-000093 · edgardoc.xml · derivative · entry 1 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-05-13 F1 · derivative.exercise_date: Options shall vest and become exercisable in 12 equal monthly installments as from the date of the grant. Read SEC document |
| April 28, 2020 Filed Apr 29, 2020 22:25 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 6,666 | $16.00 Strike: $11.04 | $106,656.00 |
DisclosureSEC source: 0001061983-20-000071 · edgardoc.xml · derivative · entry 6 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,666 shares Expires 2021-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 28, 2020 Filed Apr 29, 2020 22:25 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,333 | $16.00 Strike: $8.64 | $53,328.00 |
DisclosureSEC source: 0001061983-20-000071 · edgardoc.xml · derivative · entry 5 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,333 shares Expires 2021-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 28, 2020 Filed Apr 29, 2020 22:25 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 6,666 | $16.00 | $106,656.00 |
DisclosureSEC source: 0001061983-20-000071 · edgardoc.xml · nonDerivative · entry 4 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| April 28, 2020 Filed Apr 29, 2020 22:25 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 6,666 | $11.04 | $73,592.64 |
DisclosureSEC source: 0001061983-20-000071 · edgardoc.xml · nonDerivative · entry 3 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,666 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 28, 2020 Filed Apr 29, 2020 22:25 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 3,333 | $16.00 | $53,328.00 |
DisclosureSEC source: 0001061983-20-000071 · edgardoc.xml · nonDerivative · entry 2 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| April 28, 2020 Filed Apr 29, 2020 22:25 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 3,333 | $8.64 | $28,797.12 |
DisclosureSEC source: 0001061983-20-000071 · edgardoc.xml · nonDerivative · entry 1 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 28, 2020 Filed Apr 29, 2020 21:01 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Exercise / conversionStock Option (right to but) · Derivative | 25,329 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0001209191-20-026196 · doc4.xml · derivative · entry 2 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 25,329 shares Expires 2025-12-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares subject to the option vested on October 30, 2016, and 1/48th of the shares subject to the option vested monthly thereafter such that all of the shares subject to the option were fully vested as of October 30, 2019. Read SEC document |
| April 28, 2020 Filed Apr 29, 2020 21:01 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Exercise / conversionCommon Stock | 25,329 | $0.73 | $18,490.17 |
DisclosureSEC source: 0001209191-20-026196 · doc4.xml · nonDerivative · entry 1 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,846 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 21, 2019 Filed Jun 25, 2019 20:07 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $23.24 | $0.00 |
DisclosureSEC source: 0001209191-19-038894 · doc4.xml · derivative · entry 1 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2029-06-20 F1 · derivative.exercise_date: The entire number of shares subject to this option become fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| May 15, 2019 Filed May 17, 2019 21:10 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $10.68 Strike: $10.68 | $213,600.00 |
DisclosureSEC source: 0001061983-19-000040 · edgardoc.xml · derivative · entry 1 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-05-15 F1 · derivative.exercise_date: This option shall vest and become exercisable in 12 equal monthly installments and shall become fully vested on May 15, 2020 Read SEC document |
| June 14, 2018 Filed Jun 18, 2018 19:00 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | GrantNonstatutory Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $19.59 | $0.00 |
DisclosureSEC source: 0000899243-18-017080 · doc4.xml · derivative · entry 1 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-06-13 F1 · derivative.exercise_date: The shares underlying this option vest in equal quarterly installments over a one-year period, through and including June 14, 2019. Read SEC document |
| May 16, 2018 Filed May 17, 2018 22:29 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $9.45 Strike: $9.45 | $189,000.00 |
DisclosureSEC source: 0001061983-18-000031 · edgardoc.xml · derivative · entry 1 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-05-16 F1 · derivative.exercise_date: This option shall vest and become exercisable in 12 equal monthly installments and shall become fully vested on May 16, 2019 Read SEC document |
| January 04, 2018 Filed Jan 8, 2018 16:03 UTC | SEELOS THERAPEUTICS, INC. APRI · Entity 93662 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0001017491-18-000018 · wf-form4_151544537580041.xml · derivative · entry 1 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2028-01-04 F1 · kind: The options to purchase shares of common stock were issued to the Reporting Person, a non-employee director of Issuer, as an annual stock option grant for his service as a director of the Issuer. F2 · derivative.exercise_date: The options shall vest with respect to 1/12th of the underlying shares monthly, commencing with the first monthly vesting date of February 4, 2018, so that such options are fully vested on January 4, 2019. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 23:37 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 5,714 | $3.50 Strike: $8.75 | $20,000.14 |
DisclosureSEC source: 0001061983-18-000006 · edgardoc.xml · derivative · entry 1 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,714 Underlying: Common Stock · 5,714 shares Expires 2028-01-02 F2 · price: This option was issued to the reporting person pursuant to the Cytokinetics 2004 Equity Incentive Plan in lieu of 50% of an annual retainer of $40,000.00 F1 · derivative.exercise_date: This option shall vest and become exercisable as to 5,714 shares divided into equal monthly installments such that the option shall be 100% vested on January 2, 2019. Read SEC document |
| December 11, 2017 Filed Dec 11, 2017 15:18 UTC | Ocera Therapeutics, Inc. OCRX · Entity 171193 | Disposition to issuerStock Option (Right to Buy) · Derivative | 12,500 | Not disclosed Strike: $2.26 | Not disclosed |
DisclosureSEC source: 0000899243-17-028411 · doc4.xml · derivative · entry 6 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2026-06-13 F4 · price: Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an "In the Money Option") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR. F5 · price: (Continued from Footnote 4) All other options (each, an "Out of the Money Option") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option. Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore. F9 · price: This Out of the Money Option, which became fully vested on June 14, 2017, was cancelled in connection with the Merger in exchange for the right to receive one or more cash payments, without interest and subject to deduction for any required withholding taxes, equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds $2.26, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an "In the Money Option") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR. F5 · derivative.exercise_date: (Continued from Footnote 4) All other options (each, an "Out of the Money Option") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option. Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore. F9 · derivative.exercise_date: This Out of the Money Option, which became fully vested on June 14, 2017, was cancelled in connection with the Merger in exchange for the right to receive one or more cash payments, without interest and subject to deduction for any required withholding taxes, equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds $2.26, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option. Read SEC document |
| December 11, 2017 Filed Dec 11, 2017 15:18 UTC | Ocera Therapeutics, Inc. OCRX · Entity 171193 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,000 | Not disclosed Strike: $3.76 | Not disclosed |
DisclosureSEC source: 0000899243-17-028411 · doc4.xml · derivative · entry 5 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2025-06-17 F4 · price: Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an "In the Money Option") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR. F5 · price: (Continued from Footnote 4) All other options (each, an "Out of the Money Option") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option. Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore. F8 · price: This Out of the Money Option, which became fully vested on June 18, 2016, was cancelled in connection with the Merger in exchange for the right to receive one or more cash payments, without interest and subject to deduction for any required withholding taxes, equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds $3.76, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an "In the Money Option") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR. F5 · derivative.exercise_date: (Continued from Footnote 4) All other options (each, an "Out of the Money Option") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option. Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore. F8 · derivative.exercise_date: This Out of the Money Option, which became fully vested on June 18, 2016, was cancelled in connection with the Merger in exchange for the right to receive one or more cash payments, without interest and subject to deduction for any required withholding taxes, equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds $3.76, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option. Read SEC document |
| December 11, 2017 Filed Dec 11, 2017 15:18 UTC | Ocera Therapeutics, Inc. OCRX · Entity 171193 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,000 | Not disclosed Strike: $7.84 | Not disclosed |
DisclosureSEC source: 0000899243-17-028411 · doc4.xml · derivative · entry 4 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2024-06-11 F4 · price: Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an "In the Money Option") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR. F5 · price: (Continued from Footnote 4) All other options (each, an "Out of the Money Option") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option. Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore. F7 · price: This Out of the Money Option, which became fully vested on July 11, 2015, was cancelled in connection with the Merge for no consideration. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an "In the Money Option") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR. F5 · derivative.exercise_date: (Continued from Footnote 4) All other options (each, an "Out of the Money Option") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option. Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore. F7 · derivative.exercise_date: This Out of the Money Option, which became fully vested on July 11, 2015, was cancelled in connection with the Merge for no consideration. Read SEC document |
| December 11, 2017 Filed Dec 11, 2017 15:18 UTC | Ocera Therapeutics, Inc. OCRX · Entity 171193 | Disposition to issuerStock Option (Right to Buy) · Derivative | 20,000 | Not disclosed Strike: $13.25 | Not disclosed |
DisclosureSEC source: 0000899243-17-028411 · doc4.xml · derivative · entry 3 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2023-12-19 F4 · price: Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an "In the Money Option") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR. F5 · price: (Continued from Footnote 4) All other options (each, an "Out of the Money Option") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option. Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore. F6 · price: This Out of the Money Option, which provided for vesting with respect to 25% of such options on December 19, 2014, with the remaining 75% of such options vesting in equal monthly installments over the next succeeding three year period, was cancelled in connection with the Merger for no consideration. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an "In the Money Option") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR. F5 · derivative.exercise_date: (Continued from Footnote 4) All other options (each, an "Out of the Money Option") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option. Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore. F6 · derivative.exercise_date: This Out of the Money Option, which provided for vesting with respect to 25% of such options on December 19, 2014, with the remaining 75% of such options vesting in equal monthly installments over the next succeeding three year period, was cancelled in connection with the Merger for no consideration. Read SEC document |
| December 11, 2017 Filed Dec 11, 2017 15:18 UTC | Ocera Therapeutics, Inc. OCRX · Entity 171193 | Disposition to issuerCommon Stock | 12,500 | $1.52 | $19,000.00 |
DisclosureSEC source: 0000899243-17-028411 · doc4.xml · nonDerivative · entry 2 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to an Agreement and Plan of Merger, dated November 1, 2017 (the "Merger Agreement"), by and between Ocera Therapeutics, Inc., a Delaware corporation (the "Issuer"), MAK LLC, a Delaware limited liability company ("Parent"), MEH Acquisition Co., a Delaware corporation and a direct wholly-owned subsidiary of Parent ("Purchaser"), and for limited purposes, Mallinckrodt plc, an Irish public limited company and the ultimate parent entity of Parent and Purchaser ("Mallinckrodt"), Purchaser was merged with and into Issuer on December 11, 2017, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). F2 · price: (Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, all shares of common stock, $0.00001 par value per share (the "Shares"), of the Issuer outstanding immediately prior to the effective time of the Merger (the "Effective Time") , were canceled and converted automatically and without any required action on the part of the Reporting Person into the right to receive (i) $1.52 per Share in cash, without interest, plus (ii) one non-transferable contingent value right per Share (each, a "CVR"), which represents the contractual right under a contingent value rights agreement, by and among Parent, Continental Stock Transfer & Trust Company, and for limited purposes, Mallinckrodt (the "CVR Agreement"), entered into on December 7, 2017 to receive one or more payments in cash currently estimated to be up to $2.58 per Share, contingent upon the achievement of certain milestones, in each case, less any required withholding taxes. F3 · price: At the Effective Time of the Merger, each restricted stock unit outstanding, automatically and without any required action on the part of the Reporting Person, became fully vested and canceled in exchange for a right to receive, for each share of common stock underlying the restricted stock unit, (i) an amount in cash, equal to $1.52, without interest plus (ii) one CVR, less any required withholding taxes. Read SEC document |
| December 11, 2017 Filed Dec 11, 2017 15:18 UTC | Ocera Therapeutics, Inc. OCRX · Entity 171193 | Disposition to issuerCommon Stock | 5,000 | $1.52 | $7,600.00 |
DisclosureSEC source: 0000899243-17-028411 · doc4.xml · nonDerivative · entry 1 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to an Agreement and Plan of Merger, dated November 1, 2017 (the "Merger Agreement"), by and between Ocera Therapeutics, Inc., a Delaware corporation (the "Issuer"), MAK LLC, a Delaware limited liability company ("Parent"), MEH Acquisition Co., a Delaware corporation and a direct wholly-owned subsidiary of Parent ("Purchaser"), and for limited purposes, Mallinckrodt plc, an Irish public limited company and the ultimate parent entity of Parent and Purchaser ("Mallinckrodt"), Purchaser was merged with and into Issuer on December 11, 2017, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). F2 · price: (Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, all shares of common stock, $0.00001 par value per share (the "Shares"), of the Issuer outstanding immediately prior to the effective time of the Merger (the "Effective Time") , were canceled and converted automatically and without any required action on the part of the Reporting Person into the right to receive (i) $1.52 per Share in cash, without interest, plus (ii) one non-transferable contingent value right per Share (each, a "CVR"), which represents the contractual right under a contingent value rights agreement, by and among Parent, Continental Stock Transfer & Trust Company, and for limited purposes, Mallinckrodt (the "CVR Agreement"), entered into on December 7, 2017 to receive one or more payments in cash currently estimated to be up to $2.58 per Share, contingent upon the achievement of certain milestones, in each case, less any required withholding taxes. Read SEC document |
| June 20, 2017 Filed Jun 22, 2017 16:42 UTC | Ocera Therapeutics, Inc. OCRX · Entity 171193 | GrantCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001274644-17-000060 · wf-form4_149816410200456.xml · nonDerivative · entry 1 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 F1 · shares: These shares represent restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The restricted stock units shall vest in full on the earlier of the one year anniversary of the grant or the next annual meeting of shareholders; provided, in all cases, that the Reporting Person is, as of each such vesting date, then a director of the Issuer. Read SEC document |
| June 15, 2017 Filed Jun 19, 2017 07:35 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | GrantNonstatutory Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $13.29 | $0.00 |
DisclosureSEC source: 0001209191-17-040710 · doc4.xml · derivative · entry 1 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-06-14 F1 · derivative.exercise_date: The shares underlying this option vest in equal quarterly installments over a one-year period, through and including June 15, 2018. Read SEC document |
| May 18, 2017 Filed May 22, 2017 21:57 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $14.25 | $0.00 |
DisclosureSEC source: 0001061983-17-000035 · edgardoc.xml · derivative · entry 1 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-05-18 F1 · derivative.exercise_date: This option shall vest and become exercisable in 12 equal monthly installments and shall become fully vested on May 18, 2018. Read SEC document |
| January 05, 2017 Filed Jan 6, 2017 19:30 UTC | SEELOS THERAPEUTICS, INC. APRI · Entity 93662 | GrantCommon Stock | 11,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001017491-17-000016 · wf-form4_148374903696025.xml · nonDerivative · entry 1 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Wierenga Family Trust Disclosed balance after: 15,373 F1 · shares: The Restricted Stock Units ("RSUs") were issued to the Reporting Person, a non-employee director of the Issuer, as an annual equity grant for his service as a director of the Issuer. Such RSUs shall fully vest on the first anniversary of the grant date, January 5, 2018, and are subject to accelerated vesting upon a change of control of the Issuer. F2 · price: Not applicable. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 23:47 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 4,032 | $4.96 Strike: $12.40 | $19,999.93 |
DisclosureSEC source: 0001061983-17-000010 · edgardoc.xml · derivative · entry 1 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,032 Underlying: Common Stock · 4,032 shares Expires 2027-01-03 F2 · price: This option was issued to the reporting person pursuant to the Cytokinetics 2004 Equity Incentive Plan in lieu of 50% of an annual retainer of $40,000.00 F1 · derivative.exercise_date: This option shall vest and become exercisable as to 4,032 shares divided into equal monthly installments such that the option shall be 100% vested on January 3, 2018. Read SEC document |
| September 30, 2016 Filed Oct 3, 2016 16:33 UTC | SEELOS THERAPEUTICS, INC. APRI · Entity 93662 | GrantCommon Stock | 8,868 | $0.34 | $3,000.04 |
DisclosureSEC source: 0001017491-16-000221 · wf-form4_147552680866260.xml · nonDerivative · entry 1 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Wierenga Family Trust Disclosed balance after: 41,228 F1 · shares: The shares of common stock were issued to the Reporting Person, a non-employee director of the Issuer, as partial payment for the quarterly retainer fee for his service as director of Issuer under an amended director compensation policy, which reduced the cash compensation payable to the Issuer's non-employee directors and in lieu of such cash compensation, resolved to grant shares of the Issuer's common stock. F2 · price: The value of the shares being delivered in satisfaction of the payment was calculated based on the closing price of the Issuer's common stock on September 30, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.